While studies have confirmed that the loss of LIFR:STAT3 signaling is associated with reduced breast cancer patient survival [24,73], to date, there are no clinical studies that have rigorously tested these cytokines and their receptors in the oncology setting. This evidence concerns the gene STAT3 and breast carcinoma.